Novel Caffeic Acid Nanocarrier: Production, Characterization, and Release Modeling

Table 3

Antioxidant activity changes^a of released caffeic acid from nanocarriers in gastric and intestinal simulated condition.

Treatment	DPPH assay (%)		Reducing activity; (𝜇g/mL of caffeic acid)
	Gastric media	Intestine media	Gastric media	Intestine media
T1	5.85 ± 1.34	8.39 ± 2.56	12.44 ± 0.61	4.7 ± 0.34
T2	0.00	0.19 ± 0.09	5.3 ± 0.19	1.23 ± 0.10
T3	9.16 ± 1.04	3.7 ± 0.61	9.36 ± 1.07	0.96 ± 0.05
T4	0.00	2.15 ± 0.88	21.48 ± 0.11	0.38 ± 0.33
T5	11.24 ± 0.21	7.8 ± 1.86	5.6 ± 0.93	2.3 ± 1.28
T6	15.6 ± 3.37	0.00	0.27 ± 0.1	0.83 ± 0.23
T7	3.07 ± 0.23	3.2 ± 0.73	4.78 ± 1.16	3.84 ± 0.68

T1: caffeic acid released from solid lipid nanoparticles.
T2: caffeic acid released from solid lipid nanoparticles coated with 0.1% PEC-CH.
T3: caffeic acid released from solid lipid nanoparticles coated with 0.25% PEC-CH.
T4: caffeic acid released from solid lipid nanoparticles coated with 0.5% PEC-CH.
T5: caffeic acid released from solid lipid nanoparticles coated with 0.1% AL-CH.
T6: caffeic acid released from solid lipid nanoparticles coated with 0.25% AL-CH.
T7: caffeic acid released from solid lipid nanoparticles coated with 0.5% AL-CH.
^aResults are expressed as the means of three replications ± standard error of mean.